Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.22 Million CAD | -30.31% |
| 2022 | 1.75 Million CAD | -14.6% |
| 2021 | 2.05 Million CAD | 104.93% |
| 2020 | 1 Million CAD | 80.4% |
| 2019 | 554.89 Thousand CAD | -35.93% |
| 2018 | 866.02 Thousand CAD | 32.07% |
| 2017 | 655.74 Thousand CAD | 1153.26% |
| 2016 | 52.32 Thousand CAD | 3430.57% |
| 2015 | 1482.00 CAD | -98.43% |
| 2014 | 94.46 Thousand CAD | 108.4% |
| 2013 | 45.32 Thousand CAD | -47.0% |
| 2012 | 85.51 Thousand CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 561.5 Thousand CAD | 70.9% |
| 2024 Q1 | 328.55 Thousand CAD | 43.67% |
| 2024 Q3 | 358.73 Thousand CAD | -36.11% |
| 2023 Q2 | 621.48 Thousand CAD | 66.31% |
| 2023 Q3 | 130.69 Thousand CAD | -78.97% |
| 2023 FY | 1.34 Million CAD | -23.27% |
| 2023 Q4 | 228.69 Thousand CAD | 74.99% |
| 2023 Q1 | 373.69 Thousand CAD | -34.76% |
| 2022 Q3 | 426.82 Thousand CAD | -10.43% |
| 2022 Q1 | 247.35 Thousand CAD | -52.23% |
| 2022 Q2 | 476.51 Thousand CAD | 92.65% |
| 2022 Q4 | 572.8 Thousand CAD | 34.2% |
| 2022 FY | 1.75 Million CAD | -14.6% |
| 2021 Q1 | 79.91 Thousand CAD | -52.55% |
| 2021 FY | 2.05 Million CAD | 104.93% |
| 2021 Q4 | 517.82 Thousand CAD | 40.3% |
| 2021 Q2 | 327.2 Thousand CAD | 309.46% |
| 2021 Q3 | 369.08 Thousand CAD | 12.8% |
| 2020 Q4 | 168.42 Thousand CAD | 26.16% |
| 2020 Q3 | 133.5 Thousand CAD | -49.61% |
| 2020 Q1 | 408.64 Thousand CAD | 354.01% |
| 2020 FY | 1 Million CAD | 80.4% |
| 2020 Q2 | 264.93 Thousand CAD | -35.17% |
| 2019 Q2 | 108.1 Thousand CAD | -24.7% |
| 2019 Q4 | 90 Thousand CAD | -57.79% |
| 2019 Q3 | 213.21 Thousand CAD | 97.24% |
| 2019 FY | 554.89 Thousand CAD | -35.93% |
| 2019 Q1 | 143.56 Thousand CAD | -49.52% |
| 2018 FY | 866.02 Thousand CAD | 32.07% |
| 2018 Q1 | 141.35 Thousand CAD | 14.43% |
| 2018 Q2 | 154.77 Thousand CAD | 9.49% |
| 2018 Q3 | 285.5 Thousand CAD | 84.47% |
| 2018 Q4 | 284.39 Thousand CAD | -0.39% |
| 2017 Q1 | 45.31 Thousand CAD | 49.63% |
| 2017 Q3 | 220.05 Thousand CAD | -17.54% |
| 2017 FY | 655.74 Thousand CAD | 1153.26% |
| 2017 Q4 | 123.53 Thousand CAD | -43.86% |
| 2017 Q2 | 266.84 Thousand CAD | 488.93% |
| 2016 Q1 | 1092.00 CAD | -89.67% |
| 2016 Q2 | 15.45 Thousand CAD | 1315.11% |
| 2016 Q3 | 5496.00 CAD | -64.43% |
| 2016 Q4 | 30.28 Thousand CAD | 450.98% |
| 2016 FY | 52.32 Thousand CAD | 3430.57% |
| 2015 Q1 | 4025.00 CAD | -86.57% |
| 2015 FY | 1482.00 CAD | -98.43% |
| 2015 Q4 | 10.56 Thousand CAD | 1185.77% |
| 2015 Q2 | -16.86 Thousand CAD | -518.88% |
| 2015 Q3 | 822.00 CAD | 104.88% |
| 2014 Q1 | 5945.00 CAD | -82.45% |
| 2014 FY | 94.46 Thousand CAD | 108.4% |
| 2014 Q4 | 29.96 Thousand CAD | 213.65% |
| 2014 Q3 | 9552.00 CAD | -80.51% |
| 2014 Q2 | 49 Thousand CAD | 724.27% |
| 2013 Q3 | 1854.00 CAD | -49.69% |
| 2013 Q4 | 33.86 Thousand CAD | 1726.81% |
| 2013 Q2 | 3685.00 CAD | -37.74% |
| 2013 Q1 | 5919.00 CAD | -74.34% |
| 2013 FY | 45.32 Thousand CAD | -47.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | 23.07 Thousand CAD | 26.04% |
| 2012 FY | 85.51 Thousand CAD | 0.0% |
| 2012 Q2 | 44.14 Thousand CAD | 0.0% |
| 2012 Q3 | 18.3 Thousand CAD | -58.54% |
| 2011 FY | - CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 2.96 Million CAD | 58.807% |
| CanadaBis Capital Inc. | 7.1 Million CAD | 82.82% |
| Decibel Cannabis Company Inc. | 40.44 Million CAD | 96.981% |
| Delivra Health Brands Inc. | 7.1 Million CAD | 82.825% |
| Entourage Health Corp. | 3.7 Million CAD | 67.07% |
| Lifeist Wellness Inc. | 17.59 Million CAD | 93.061% |
| Cannara Biotech Inc. | 15.34 Million CAD | 92.042% |
| Medicure Inc. | 13.98 Million CAD | 91.272% |
| PharmaCielo Ltd. | 8.33 Million CAD | 85.346% |
| Rubicon Organics Inc. | 14.22 Million CAD | 91.416% |
| BioSyent Inc. | 17.6 Million CAD | 93.066% |